Racial Differences in Esophageal Squamous Cell Carcinoma: Incidence and Molecular Features

Chen, Shirui; Zhou, Kai; Yang, Liguang; Ding, Guohui; Li, Hong

doi:10.1155/2017/1204082

Cited by 24 publications

(36 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26] However, most of these papers were case studies and only applied to adenocarcinoma of the esophagus, but not to squamous cell carcinoma, which is the main type of EC worldwide [6] and accounts for 90% of EC in China. [27] In the present study, most of the neoplastic lesions we collected were pathologically diagnosed squamous intraepithelial neoplasia and squamous cell carcinoma, and thus our results are representative. Moreover, the white substance can attract the attention of endoscopists and is easier to detect because it is obvious in esophageal lesions under WLE, without requiring the auxiliary use of NBI or ME.…”

Section: Discussionmentioning

confidence: 65%

The white substance may be a potential endoscopic marker for flat esophageal mucosal neoplastic lesions

Yang

Du²,

Zhang³

et al. 2018

Medicine

View full text Add to dashboard Cite

To determine whether the white substance can act as an endoscopic marker for flat esophageal mucosal neoplastic lesions.Esophageal mucosal neoplastic lesions are mainly identified using white light endoscopy, because it is cost-effective; however, this method is limited for detecting early esophageal cancer and precancerous lesions, because these are typically flat mucosal neoplastic lesions. In our experience, a white substance surrounds or covers some flat esophageal mucosal lesions that are eventually diagnosed as neoplastic lesions by biopsy pathology.After retrospective analysis of pathological and clinical data of 20,390 patients, we identified 352 patients with flat esophageal mucosal lesions on endoscopic images. Images were re-evaluated by 2 experienced endoscopists and the prevalence of the white substance recorded. Patients were divided into non-neoplastic and neoplastic groups, based on pathology.The white substance was present in 3.5% (5/144) of non-neoplastic and 14.9% (31/208) of neoplastic cases (P < .05). The diagnostic sensitivity and specificity of the white substance for neoplastic lesions diagnosis were 14.9% and 96.5%, respectively. The presence of white substance was more common in males and in those aged 50 to 79 years. It was more commonly observed in the middle third of the esophagus, and its presence did not correlate with sex, age, or lesion location (P > .05).The white substance, which is easily detected by white light endoscopy, may be an endoscopic marker facilitating detection of flat esophageal mucosal neoplastic lesions, irrespective of sex, age, and lesion location.

show abstract

Section: Discussionmentioning

confidence: 65%

The white substance may be a potential endoscopic marker for flat esophageal mucosal neoplastic lesions

Yang

Du²,

Zhang³

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, we found COL14A1 promoter methylation levels slightly higher in ESCC when compared with normal esophagus samples, although not statistically signi cant. This can be partially explained by variations in the population (Asian vs. Caucasian), as previously attested for some genes (42), and the different nature of samples tested (plasma vs. FFPE). Notwithstanding, COL14A1 promoter methylation levels were signi cantly lower in EA compared to normal.…”

Section: Discussionmentioning

confidence: 94%

A DNA Methylation-based Test for Esophageal Cancer Detection

Salta

Macedo-Silva

Miranda‐Gonçalves

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Esophageal cancer (ECa) is the 7 th most incident cancer and the 6 th leading cause of cancer-related death. Most patients are diagnosed with locally advanced or metastatic disease, enduring poor survival. Biomarkers enabling early cancer detection may improve patient management, treatment effectiveness, and survival, are urgently needed. In this context, epigenetic-based biomarkers such as DNA methylation are potential candidates. Methods: Herein, we sought to identify and validate DNA methylation-based biomarkers for early detection and prediction of response to therapy in ECa patients. Promoter methylation levels were assessed in a series of treatment-naïve ECa, post-neoadjuvant treatment ECa, and normal esophagus tissues, using quantitative methylation-specific PCR for COL14A1 , GPX3, and ZNF569 . Results: ZNF569 methylation ( ZNF569me) levels significantly differed between ECa and normal samples ( p <0.001). Moreover, COL14A1 methylation ( COL14A1me) and GPX3 methylation ( GPX3me) levels discriminated adenocarcinomas and squamous cell carcinomas, respectively, from normal samples ( p =0.002 and p =0.009, respectively). COL14A1me & ZNF569me accurately identified adenocarcinomas (82.29%) whereas GPX3me & ZNF569me identified squamous cell carcinomas with 81.73% accuracy. Furthermore, ZNF569me and GPX3me levels significantly differed between normal and pre-treated ECa. Conclusion: The biomarker potential of a specific panel of methylated genes for ECa was confirmed. These might prove useful for early detection and might allow for the identification of minimal residual disease after adjuvant therapy.

show abstract

“…We found COL14A1 promoter methylation levels slightly higher in ESCC, although not statistically signi cant. This can be partially explained by variations in population (Asian vs. Caucasian), as previously attested for some genes (40), and different nature of samples tested (plasma vs. FFPE). Notwithstanding, COL14A1 promoter methylation levels were signi cantly lower in EA compared to normal.…”

Section: Discussionmentioning

confidence: 97%

A DNA Methylation-based Test for Esophageal Cancer Detection

Salta

Macedo-Silva

Miranda‐Gonçalves

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Esophageal cancer (ECa) is the 7th most incident cancer and the 6th leading cause of cancer-related death. Most patients are diagnosed with locally advanced or metastatic disease, enduring poor survival. Biomarkers enabling early cancer detection may improve patient management, treatment effectiveness and survival are urgently needed. In this context, epigenetic-based biomarkers such as DNA methylation are potential candidates. Methods Herein, we sought to identify and validate DNA methylation-based biomarkers for early detection and prediction of response to therapy in ECa patients. Promoter methylation levels were assessed in a series of treatment-naïve ECa, post-neoadjuvant treatment ECa and normal esophagus tissues, using quantitative methylation-specific PCR for COL14A1, GPX3, and ZNF569. Results ZNF569 methylation (ZNF569me) levels significantly differed between ECa and normal samples. Moreover, COL14A1 methylation (COL14A1me) and GPX3 methylation (GPX3me) levels discriminated adenocarcinomas and squamous cell carcinomas, respectively, from normal samples. COL14A1me & ZNF569me accurately identified adenocarcinomas (82.29%) whereas GPX3me & ZNF569me identified squamous cell carcinomas with 81.73% accuracy. Furthermore, ZNF569me and GPX3me levels significantly differed between normal and pre-treated ECa. Conclusion The biomarker potential of a specific panel of methylated genes for ECa was confirmed. These might prove useful for early detection and might allow for identification of minimal residual disease after adjuvant therapy.

show abstract

Racial Differences in Esophageal Squamous Cell Carcinoma: Incidence and Molecular Features

Cited by 24 publications

References 31 publications

The white substance may be a potential endoscopic marker for flat esophageal mucosal neoplastic lesions

The white substance may be a potential endoscopic marker for flat esophageal mucosal neoplastic lesions

A DNA Methylation-based Test for Esophageal Cancer Detection

A DNA Methylation-based Test for Esophageal Cancer Detection

Contact Info

Product

Resources

About